胆固醇系统的变化在多巴不响应的结行走在帕金森病的疾病
Kelvin L Chou1,2,3, Prabesh Kanel2,3,4,5, Miriam van Emde Boas2,3,4
1Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA.
概括
在帕金森病 (PD) 中对levodopa无反应的步态结 (FoG) 与广泛的胆固醇缺陷有关,特别是在条形体外. 这些变化可能解释了为什么一些FOG病例会抵抗标准PD治疗.
科学领域:
- 神经科学是一个神经科学.
- 运动障碍 运动障碍
- 放射化学 放射化学是指辐射化学.
背景情况:
- 步态结 (FoG) 是帕金森病 (PD) 中的一个显著的移动性问题,该病通常会对利沃多巴治疗产生抵抗力.
- 勒沃多巴耐药FoG的确切原因尚不完全理解,但胆固醇通路退化与此有关.
研究的目的:
- 研究胆固醇系统的特定变化与FOG对PD患者的乐伏多巴反应程度之间的关联.
- 在FOG中识别潜在的勒沃多巴响应的成像生物标志物.
主要方法:
- 使用[18F]FEOBV囊性乙胆载体正子发射断层扫描 (VAChT PET) 来评估36名PD患者的胆性终端.
- 在Levodopa治疗期间和之后对FoG进行了临床评估.
- 进行了基于voxel的分析,将[18F]FEOBV PET数据与对levodopa反应和不反应的FOG组进行比较.
主要成果:
- 十六名受试者表现出对利沃多巴无反应的FoG.
- 没有响应levodopa的FoG患者在额外状区域 (包括insula,海马和thalamus) 中表现出更严重的胆固醇终端缺陷.
- 在特定的纹状和状区域也发现了缺陷,但这种模式与响应的FOG不同.
结论:
- 在PD中,对levodopa不响应的FoG与胆固醇终端的广泛减少有关,主要是对于步态和认知整合至关重要的额外状区域.
- 这些发现表明,大脑广泛网络功能的干扰,而不是仅仅是条纹病理,是治疗耐药的FoG的基础.
- 这突显了FoG复杂的病理生理学及其对多巴胺疗法的耐药性.
相关概念视频
01:24Parkinson's Disease: Treatment
158
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
158
01:15Parkinson's Disease: Overview
334
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
334
01:28Cholinergic Antagonists: Pharmacological Actions
735
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
735
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
573
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
573
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
1.1K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.1K
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.5K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.5K